Maoxuan Liu
Medical School
University of Chinese Academy of Sciences
Guangdong
Language: Chinese, English
Contact
Gene Therapy Immune Cells Car-T Cells Natural Medicines Active Substances Function Biotechnology Cancer Treatment Immunotherapy Pharmacology
Areas of Focus
  • Gene-modified immune cell therapy technology
  • Active substances and functions of natural medicines
Work Experience
  • 2023-01~Present - Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences - Associate Researcher
  • 2020-09~2022-12 - Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences - Assistant Researcher
  • 2018-10~2020-09 - Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences - Postdoctoral Researcher
Academic Background & Achievements
  • 2014-09--2018-09 PhD: KU Leuven
  • 2011-09--2014-06 Master's: Shandong University
  • 2007-09--2011-06 Bachelor's: Shandong University
Publications
  • NKG2D chimeric antigen receptor-expressing macrophages demonstrate cytotoxicity against tumor cells, Third Author, 2022
  • Comparative Study of the Efficacy of Two Mesothelin-targeting CAR-T Cells Against Triple Negative Breast Cancer, Second Author, 2022
  • CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro, First Author, 2022
  • Bioassay-Guided Isolation of Anthelmintic Components from Semen pharbitidis, and the Mechanism of Action of Pharbitin, Corresponding Author, 2022
  • GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay, Third Author, 2022
  • CD317 mediates immunocytolysis resistance by RICH2/cytoskeleton-dependent membrane protection, Fifth Author, 2021
  • Antibacterial, Antifungal, Antiviral, and Anthelmintic Activities of Medicinal Plants of Nepal Selected Based on Ethnobotanical Evidence, Fourth Author, 2020
  • A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro, Ninth Author, 2020
  • Plant-Based Natural Products for the Discovery and Development of Novel Anthelmintics against Nematodes, First Author, 2020
  • Biofilm inhibiting properties of compounds from the leaves of Warburgia ugandensis Sprague subsp ugandensis against Candida and staphylococcal biofilms, Second Author, 2020
  • Screening of a drug repurposing library with a nematode motility assay identifies promising anthelmintic hits against Cooperia oncophora and other ruminant parasites, Corresponding Author, 2019
  • Bioassay-guided isolation of anti-seizure principles from Semen Pharbitidis using a zebrafish pentylenetetrazol seizure model, Corresponding Author, 2019
  • Bioassay-guided isolation of active substances from Semen Torreyae identifies two new anthelmintic compounds with novel mechanism of action, Corresponding Author, 2018
  • Active principles of Tetradenia riparia. IV. Anthelmintic activity of 8(14),15-sandaracopimaradiene-7 alpha,18-diol, Corresponding Author, 2018
  • Bioassay-guided isolation of three anthelmintic compounds from Warburgia ugandensis Sprague subspecies ugandensis, and the mechanism of action of polygodial, Corresponding Author, 2018
  • Antimicrobial, Anthelmintic, and Antiviral Activity of Plants Traditionally Used for Treating Infectious Disease in the Similipal Biosphere Reserve, Odisha, India, Fourth Author, 2017
  • A novel pentapeptide originated from calf thymus named TIPP shows an inhibitory effect on lung allergic inflammation, Fifth Author, 2015
  • Hematopoietic effects and mechanisms of Fufang E'jiao Jiang on radiotherapy and chemotherapy-induced myelosuppressed mice, First Author, 2014
  • Therapeutic effects of Fufang E'jiao Jiang on renal anemia rats and its mechanisms, First Author, 2014
  • Effect of Colla corii asini (E'jiao) on D-Galactose Induced Aging Mice, Second Author, 2012
Post a Project

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.